论文部分内容阅读
目的:评价镁铝匹林(阿司匹林、甘羟铝、重质碳酸镁复方制剂)对心血管患者血小板聚集功能的影响。方法:选择需要服用阿司匹林抗血小板治疗且ADP诱导的血小板聚集率增高的患者223例,随机分为两组,即镁铝匹林组(113例)和阿司匹林组(110例),试验组给予镁铝匹林2片(含阿司匹林162 mg),对照组给予阿斯匹林150 mg口服。于用药前及用药6周后分别测定血小板聚集率。结果:两组的血小板聚集率均显著降低,组内比较有极显著差异。组间比较无显著差异(P=0.51)。两组患者血小板聚集抑制率分别为-(20.28±22.45)%,-(21.57±23.67)%。镁铝匹林组药物不良反应较阿司匹林组少。结论:镁铝匹林与普通阿司匹林对患者血小板聚集功能的作用无明显差别。镁铝匹林比普通阿司匹林不良反应少。
OBJECTIVE: To evaluate the effects of aspirin (aspirin, glycopyrronate, and heavy magnesium carbonate) on platelet aggregation in patients with cardiovascular disease. Methods: A total of 223 patients who needed aspirin antiplatelet therapy and ADP-induced platelet aggregation rate were randomly divided into two groups: magnesium apathetic group (n = 113) and aspirin group (n = 110) Two aspirin (including aspirin 162 mg), the control group given aspirin 150 mg orally. The platelet aggregation rate was measured before treatment and 6 weeks after treatment. Results: The platelet aggregation rate was significantly decreased in both groups, with significant differences in the groups. There was no significant difference between groups (P = 0.51). The inhibition rates of platelet aggregation in the two groups were - (20.28 ± 22.45)% and - (21.57 ± 23.67)%, respectively. Adverse drug reactions in the aspirin group were less than those in the aspirin group. Conclusion: There is no significant difference between the patients with platelet aggregation and the effects of aspirin and common aspirin. Magnesium aluminum than ordinary aspirin adverse reactions.